Article

263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)

2022-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d0c20234-73eb-5c5b-bb79-24c6a1e5b9b5
DOI: 10.1016/j.annonc.2022.07.302

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)DOI 10.1016/j.annonc.2022.07.302Read

353P Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2Semantic proximity Read

Prevalence and outcomes of germline pathogenic variants of homologous recombination repair genes in ovarian cancer.Semantic proximity Read

RE: Heterozygous BRCA1 and BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.Semantic proximity Read

478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK studySemantic proximity Read

Germline RBBP6 mutations in familial myeloproliferative neoplasmsSemantic proximity Read

Genomic profiling of young-onset g<i>BRCA1/2</i> breast cancer reveals distinct genomic landscapes and therapeutic implications for PARP and CDK4/6 inhibitor selectionSemantic proximity Read

Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancerSemantic proximity Read

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read

Homologous Recombination Deficiency Among Patients with Germline or Somatic non-BRCA1/2 Homologous Recombination Repair Gene VariationsSemantic proximity Read

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug responseSemantic proximity Read

Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)Semantic proximity Read

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric studySemantic proximity Read